New Drugs to Market – October Update
Phillip Berry | Oct 25th, 2024
The Food and Drug Administration (FDA) approved three novel drug therapies in October. One of those therapies, Hympavzi (marstacimab-hncq), is a medication indicated for the treatment of patients with Hemophilia A and Hemophilia B. Hympavzi utilizes a new pathway to help reduce the risk of bleeding episodes in patients with Hemophilia, a disease that impacts … more »